Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial
The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study w...
Saved in:
Published in | European heart journal Vol. 37; no. 38; pp. 2858 - 2865 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
07.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.
Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.
Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.
ClinicalTrials.gov identifier: NCT01490814. |
---|---|
AbstractList | The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.
Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.
Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.
ClinicalTrials.gov identifier: NCT01490814. The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.AIMSThe primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.METHODS AND RESULTSPatients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.CONCLUSIONPatients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.ClinicalTrials.gov identifier: NCT01490814.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01490814. AIMS: The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation. METHODS AND RESULTS: Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up. CONCLUSION: Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation |
Author | Fürnkranz, Alexander Metzner, Andreas Tondo, Claudio Lim, Hae W. Schlüter, Michael Albenque, Jean-Paul Sticherling, Christian Chun, K.R. Julian Kueffer, Fred J. Arentz, Thomas Kühne, Michael Kuck, Karl-Heinz Brugada, Josep Ouyang, Feifan Elvan, Arif |
AuthorAffiliation | 1 Department of Cardiology, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany 3 Isala Klinieken, Zwolle, The Netherlands 8 Universitätsspital Basel, Basel, Switzerland 5 Herz-Zentrum, Bad Krozingen, Germany 4 Medtronic, Inc., Minneapolis, MN, USA 6 Clinique Pasteur, Toulouse, France 7 Centro Cardiologico Monzino, University of Milan, Milan, Italy 2 Cardioangiologisches Centrum Bethanien, Frankfurt, Germany 9 Hospital Clinic, University of Barcelona, Barcelona, Spain |
AuthorAffiliation_xml | – name: 9 Hospital Clinic, University of Barcelona, Barcelona, Spain – name: 4 Medtronic, Inc., Minneapolis, MN, USA – name: 2 Cardioangiologisches Centrum Bethanien, Frankfurt, Germany – name: 6 Clinique Pasteur, Toulouse, France – name: 8 Universitätsspital Basel, Basel, Switzerland – name: 5 Herz-Zentrum, Bad Krozingen, Germany – name: 7 Centro Cardiologico Monzino, University of Milan, Milan, Italy – name: 1 Department of Cardiology, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany – name: 3 Isala Klinieken, Zwolle, The Netherlands |
Author_xml | – sequence: 1 givenname: Karl-Heinz surname: Kuck fullname: Kuck, Karl-Heinz – sequence: 2 givenname: Alexander surname: Fürnkranz fullname: Fürnkranz, Alexander – sequence: 3 givenname: K.R. Julian surname: Chun fullname: Chun, K.R. Julian – sequence: 4 givenname: Andreas surname: Metzner fullname: Metzner, Andreas – sequence: 5 givenname: Feifan surname: Ouyang fullname: Ouyang, Feifan – sequence: 6 givenname: Michael surname: Schlüter fullname: Schlüter, Michael – sequence: 7 givenname: Arif surname: Elvan fullname: Elvan, Arif – sequence: 8 givenname: Hae W. surname: Lim fullname: Lim, Hae W. – sequence: 9 givenname: Fred J. surname: Kueffer fullname: Kueffer, Fred J. – sequence: 10 givenname: Thomas surname: Arentz fullname: Arentz, Thomas – sequence: 11 givenname: Jean-Paul surname: Albenque fullname: Albenque, Jean-Paul – sequence: 12 givenname: Claudio surname: Tondo fullname: Tondo, Claudio – sequence: 13 givenname: Michael surname: Kühne fullname: Kühne, Michael – sequence: 14 givenname: Christian surname: Sticherling fullname: Sticherling, Christian – sequence: 15 givenname: Josep surname: Brugada fullname: Brugada, Josep |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27381589$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uk1v1DAQtVAR3RbunJCPHBpqO7HjcECqli2sVIGEQOJmOd4x6yqJt7ZTmv4qfiLe7nYFSBys0Xy898Yzc4KOBj8AQi8peUNJU57DGNagQ7o-h_VPJvkTNKOcsaIRFT9CM0IbXgghvx-jkxivCSFSUPEMHbO6lJTLZoZ-zcPkW9113g_YBxz0ynkb4GaEwUxYt51OLqdszsWp3yTf54DBGx383RR73WGdgsvGuja4blf-FgdwQ4JwC8PWP8v-2seNS7pz93oX0sMK34w5kKbC26JzFrAfk_E9ROwGnNaAL5dfFvji03u8nC_wg85z9NTqLsKLvT1F3y4XX-cfi6vPH5bzi6vCcFKlompZw0pdyaaxLTGiFg2tG1sCBanLWlhJqlVJRMtabiWlWpKWc1nZsjGgoSxP0bsd72Zse1iZ_JGgO7UJrtdhUl479XdmcGv1w98qTmpSVTIT0B2BiaNRAQwEo9MD8OBsHyM1UyVhRJKMeb0XDT5vICbVu2ggT3UAP0ZFJRM1pbziufTVn_0dGntcbS4Qe_3gYwxglcnj344-t-s6RYna3pA63JDa3VAGkn-Aj9z_hfwGAYbUFQ |
CitedBy_id | crossref_primary_10_1186_s12872_022_03015_8 crossref_primary_10_1002_clc_24092 crossref_primary_10_1093_eurheartj_ehw458 crossref_primary_10_1111_jce_13936 crossref_primary_10_1136_openhrt_2018_000949 crossref_primary_10_1093_europace_euad374 crossref_primary_10_1111_jce_15317 crossref_primary_10_1155_2018_3629384 crossref_primary_10_1016_j_ahj_2019_12_006 crossref_primary_10_1093_europace_euae103 crossref_primary_10_4070_kcj_2024_0044 crossref_primary_10_1038_s41591_024_03114_3 crossref_primary_10_17925_EJAE_2022_8_1_13 crossref_primary_10_17802_2306_1278_2018_7_2_137_145 crossref_primary_10_1007_s00380_021_01963_3 crossref_primary_10_1016_j_hrthm_2017_05_029 crossref_primary_10_1016_j_ijcard_2017_06_046 crossref_primary_10_1093_eurheartj_ehw344 crossref_primary_10_1007_s10840_020_00725_x crossref_primary_10_1111_jce_15308 crossref_primary_10_1007_s10840_017_0277_z crossref_primary_10_1111_jce_14459 crossref_primary_10_1253_circj_CJ_21_0094 crossref_primary_10_1136_bmj_n379 crossref_primary_10_1007_s00059_017_4567_0 crossref_primary_10_1136_heartjnl_2018_313057 crossref_primary_10_1016_j_hrthm_2017_10_038 crossref_primary_10_3390_jcm11195862 crossref_primary_10_1016_j_ijcard_2019_02_054 crossref_primary_10_1111_pace_13810 crossref_primary_10_2459_JCM_0000000000000688 crossref_primary_10_1253_circj_CJ_20_0255 crossref_primary_10_1016_j_ijcha_2020_100576 crossref_primary_10_1016_j_jacc_2020_02_025 crossref_primary_10_1093_eurheartj_ehw674 crossref_primary_10_1016_j_hjc_2023_03_008 crossref_primary_10_1016_j_joa_2017_08_001 crossref_primary_10_1136_openhrt_2021_001718 crossref_primary_10_1093_ehjopen_oeae065 crossref_primary_10_1253_circrep_CR_19_0125 crossref_primary_10_1007_s10840_022_01321_x crossref_primary_10_17925_EJAE_2018_4_2_56 crossref_primary_10_1253_circj_CJ_18_1035 crossref_primary_10_3390_jcdd11120385 crossref_primary_10_3904_kjm_2022_97_1_5 crossref_primary_10_1111_jcpt_12671 crossref_primary_10_1111_pace_14341 crossref_primary_10_1093_europace_euaa406 crossref_primary_10_1055_a_1811_8195 crossref_primary_10_1016_j_cjca_2019_05_024 crossref_primary_10_1016_j_jacep_2020_08_041 crossref_primary_10_18501_arrhythmia_2018_012 crossref_primary_10_1038_s41598_025_90920_5 crossref_primary_10_1111_jce_15446 crossref_primary_10_1016_j_recesp_2020_10_022 crossref_primary_10_1253_circj_CJ_19_0151 crossref_primary_10_1007_s10840_022_01388_6 crossref_primary_10_1016_j_ahj_2019_04_015 crossref_primary_10_1007_s11936_020_00840_y crossref_primary_10_1186_s13019_024_03332_3 crossref_primary_10_1093_eurheartj_ehae373 crossref_primary_10_1161_CIRCEP_121_010040 crossref_primary_10_3390_jcm11051166 crossref_primary_10_1024_1661_8157_a002725 crossref_primary_10_1016_j_ijcard_2019_10_053 crossref_primary_10_1007_s10840_020_00748_4 crossref_primary_10_1016_j_cpcardiol_2022_101383 crossref_primary_10_5604_01_3001_0010_7497 crossref_primary_10_1007_s10840_023_01718_2 crossref_primary_10_1161_CIR_0000000000001193 crossref_primary_10_1016_j_jacep_2022_04_011 crossref_primary_10_1007_s10840_021_01035_6 crossref_primary_10_3390_jcdd9030088 crossref_primary_10_1007_s00392_019_01580_1 crossref_primary_10_2217_fca_2020_0066 crossref_primary_10_1111_jce_16561 crossref_primary_10_1002_joa3_12780 crossref_primary_10_1007_s10840_024_01771_5 crossref_primary_10_15420_usc_2017_28_3 crossref_primary_10_1007_s10840_019_00564_5 crossref_primary_10_1007_s10840_019_00601_3 crossref_primary_10_1007_s10840_019_00542_x crossref_primary_10_1007_s10840_019_00588_x crossref_primary_10_36516_jocass_1124247 crossref_primary_10_31083_j_rcm2502071 crossref_primary_10_1007_s10840_022_01349_z crossref_primary_10_17802_2306_1278_2018_7_4S_6_14 crossref_primary_10_1007_s10840_020_00893_w crossref_primary_10_1016_j_jacep_2018_11_006 crossref_primary_10_1093_europace_euz142 crossref_primary_10_1371_journal_pone_0270642 crossref_primary_10_1007_s10840_022_01195_z crossref_primary_10_2174_0929867324666170918122502 crossref_primary_10_1007_s00380_019_01386_1 crossref_primary_10_1111_chd_12859 crossref_primary_10_29328_journal_jccm_1001090 crossref_primary_10_1093_europace_euab281 crossref_primary_10_1093_europace_euac131 crossref_primary_10_11613_BM_2019_020902 crossref_primary_10_1371_journal_pone_0259999 crossref_primary_10_1016_j_ijcard_2018_10_097 crossref_primary_10_1093_europace_euad106 crossref_primary_10_1016_j_ijcard_2018_07_051 crossref_primary_10_1136_openhrt_2023_002423 crossref_primary_10_1007_s10840_025_01982_4 crossref_primary_10_1007_s00399_021_00836_6 crossref_primary_10_1016_j_jjcc_2019_01_004 crossref_primary_10_1093_europace_euz155 crossref_primary_10_1253_circj_CJ_16_1334 crossref_primary_10_1007_s11845_021_02560_z crossref_primary_10_1016_j_hrthm_2024_03_017 crossref_primary_10_1038_s41598_021_96820_8 crossref_primary_10_1111_jce_16220 crossref_primary_10_1186_s13063_024_07971_8 crossref_primary_10_36660_abc_20190307 crossref_primary_10_1161_CIRCRESAHA_120_316402 crossref_primary_10_1007_s10840_023_01494_z crossref_primary_10_1016_j_jjcc_2019_02_006 crossref_primary_10_1007_s10840_019_00591_2 crossref_primary_10_17816_clinpract8178_82 crossref_primary_10_1007_s10840_020_00927_3 crossref_primary_10_1080_17434440_2017_1358086 crossref_primary_10_1016_j_tcm_2016_12_002 crossref_primary_10_1007_s12325_023_02765_x crossref_primary_10_1186_s40359_023_01457_z crossref_primary_10_1161_JAHA_117_006043 crossref_primary_10_1080_20479700_2023_2290341 crossref_primary_10_1007_s00399_022_00843_1 crossref_primary_10_1016_j_hrthm_2017_05_003 crossref_primary_10_1007_s00392_020_01751_5 crossref_primary_10_1111_jce_15246 crossref_primary_10_35336_VA_2022_4_07 crossref_primary_10_1111_jce_16337 crossref_primary_10_1186_s12872_017_0566_6 crossref_primary_10_1186_s43044_024_00518_x crossref_primary_10_1007_s12181_017_0146_0 crossref_primary_10_4264_numa_77_1_7 crossref_primary_10_1093_europace_euae095 crossref_primary_10_1002_joa3_13082 crossref_primary_10_1016_j_jacc_2017_06_039 crossref_primary_10_1007_s10840_022_01132_0 crossref_primary_10_1111_jce_15009 crossref_primary_10_1007_s10840_021_01052_5 crossref_primary_10_1093_europace_euaa055 crossref_primary_10_1371_journal_pone_0206362 crossref_primary_10_1093_europace_euad329 crossref_primary_10_31083_j_rcm2504140 crossref_primary_10_1016_j_vhri_2019_05_004 crossref_primary_10_1016_j_hlc_2019_07_020 crossref_primary_10_1093_europace_euab029 crossref_primary_10_1016_j_hrthm_2017_05_012 crossref_primary_10_1111_jce_14271 crossref_primary_10_1007_s00380_021_01785_3 crossref_primary_10_1016_j_jacep_2020_04_017 crossref_primary_10_1097_MS9_0000000000002858 crossref_primary_10_17116_Cardiobulletin20221701152 crossref_primary_10_1007_s10840_018_0335_1 crossref_primary_10_4103_IJHR_IJHR_6_17 crossref_primary_10_1111_jce_14741 crossref_primary_10_1093_europace_eux274 crossref_primary_10_1161_CIRCULATIONAHA_119_042622 crossref_primary_10_15420_ecr_2019_8_1 crossref_primary_10_15836_ccar2017_240 crossref_primary_10_1093_europace_eux275 crossref_primary_10_1253_circj_CJ_19_0766 crossref_primary_10_1115_1_4047134 crossref_primary_10_1161_JAHA_118_010777 crossref_primary_10_3389_fcvm_2021_664647 crossref_primary_10_1097_JCN_0000000000000646 crossref_primary_10_1002_clc_23951 crossref_primary_10_1111_pace_13077 crossref_primary_10_3390_diagnostics12061322 crossref_primary_10_1007_s00399_023_00972_1 crossref_primary_10_1111_jce_14972 crossref_primary_10_1016_j_clinthera_2018_11_008 crossref_primary_10_1111_jce_13648 crossref_primary_10_17116_Cardiobulletin20181303110 crossref_primary_10_24060_2076_3093_2018_8_4_303_309 crossref_primary_10_36660_abc_20200204 crossref_primary_10_1016_j_jval_2019_02_001 crossref_primary_10_1016_j_jacep_2018_12_004 crossref_primary_10_1093_eurheartj_ehw629 crossref_primary_10_1016_j_cjca_2024_07_021 crossref_primary_10_3389_fcvm_2022_853149 crossref_primary_10_1161_JAHA_120_020506 crossref_primary_10_1016_j_jacep_2018_07_007 crossref_primary_10_1007_s10840_023_01680_z crossref_primary_10_1111_jce_15383 crossref_primary_10_3390_jcm11247400 crossref_primary_10_1007_s10840_022_01411_w crossref_primary_10_1016_j_ipej_2020_09_003 crossref_primary_10_1093_europace_eux050 crossref_primary_10_1007_s00380_019_01471_5 crossref_primary_10_2139_ssrn_4151282 crossref_primary_10_1093_europace_euae043 crossref_primary_10_1097_RTI_0000000000000441 crossref_primary_10_1053_j_jvca_2020_03_002 crossref_primary_10_1016_j_cjca_2025_02_033 crossref_primary_10_1038_nrcardio_2016_141 crossref_primary_10_1093_eurheartj_suab089 crossref_primary_10_1007_s10840_018_0483_3 crossref_primary_10_3390_biomedicines10020450 crossref_primary_10_1093_eurheartj_ehaa612 crossref_primary_10_15420_aer_2021_46 crossref_primary_10_1016_j_repce_2019_05_026 crossref_primary_10_1093_europace_eux066 crossref_primary_10_1093_europace_euaa132 crossref_primary_10_1161_CIRCEP_118_006989 crossref_primary_10_3390_jcdd10020055 crossref_primary_10_1016_j_amjms_2019_06_004 crossref_primary_10_1007_s12170_021_00668_6 crossref_primary_10_1042_BSR20193128 crossref_primary_10_1080_14779072_2021_1941875 crossref_primary_10_1016_j_hrthm_2018_04_021 crossref_primary_10_1016_j_ijcard_2024_132557 crossref_primary_10_1016_j_repc_2019_05_013 crossref_primary_10_18663_tjcl_1526770 crossref_primary_10_3390_jcm12247556 crossref_primary_10_1016_j_ijcha_2023_101244 crossref_primary_10_4070_kcj_2019_0226 crossref_primary_10_1002_clc_22782 crossref_primary_10_1093_europace_euab318 crossref_primary_10_17116_hirurgia202106226 crossref_primary_10_1161_JAHA_117_007559 crossref_primary_10_3390_biomedicines11071825 crossref_primary_10_1161_CIRCEP_119_007247 crossref_primary_10_1080_17434440_2019_1653181 crossref_primary_10_1016_j_ijcha_2021_100847 crossref_primary_10_1093_europace_euac094 crossref_primary_10_1097_HCO_0000000000000942 crossref_primary_10_1111_jce_13209 crossref_primary_10_1007_s00059_017_4565_2 crossref_primary_10_1093_europace_euy208 crossref_primary_10_1016_j_hjc_2024_05_011 crossref_primary_10_1016_j_hrthm_2016_12_007 crossref_primary_10_1111_pace_14130 crossref_primary_10_1002_clc_22653 crossref_primary_10_1253_circj_CJ_21_0608 crossref_primary_10_1007_s12265_018_9844_7 crossref_primary_10_1161_CIRCEP_118_006204 crossref_primary_10_1111_pace_13975 crossref_primary_10_1111_pace_14943 crossref_primary_10_1007_s10840_019_00694_w crossref_primary_10_1007_s10840_023_01645_2 crossref_primary_10_1111_pace_13858 crossref_primary_10_1097_HCO_0000000000000932 crossref_primary_10_1111_pace_14709 crossref_primary_10_1016_j_hrcr_2019_02_008 crossref_primary_10_1093_europace_euz313 crossref_primary_10_4264_numa_78_1_21 crossref_primary_10_1016_j_jacc_2023_08_017 crossref_primary_10_1016_j_joa_2017_07_001 crossref_primary_10_18087_cardio_2022_6_n1667 crossref_primary_10_1136_heartjnl_2021_319382 crossref_primary_10_1093_europace_euz309 crossref_primary_10_1016_j_jccase_2021_05_007 crossref_primary_10_1111_pace_14149 crossref_primary_10_1111_jce_13103 crossref_primary_10_1186_s12933_024_02388_8 crossref_primary_10_1111_jce_14551 crossref_primary_10_1093_europace_euy239 crossref_primary_10_4103_ijhr_ijhr_12_21 crossref_primary_10_6061_clinics_2020_e1672 crossref_primary_10_1007_s10554_021_02493_9 crossref_primary_10_1093_europace_euz318 crossref_primary_10_1161_CIRCEP_117_005955 crossref_primary_10_1007_s15027_016_0960_5 crossref_primary_10_1016_j_hrthm_2017_07_009 |
Cites_doi | 10.1161/CIRCULATIONAHA.115.016871 10.1016/j.jacc.2011.08.068 10.1093/eurheartj/ehn024 10.1056/NEJM199809033391003 10.1111/j.1540-8159.2004.00620.x 10.1186/s12955-014-0156-6 10.1111/jce.12529 10.1056/NEJMoa1408288 10.1093/europace/eus027 10.1111/j.1524-4733.2006.00108.x 10.1161/CIRCULATIONAHA.104.518837 10.1186/1471-2261-13-1 10.5603/CJ.a2015.0037 10.1056/NEJMoa1602014 |
ContentType | Journal Article |
Contributor | Universitat de Barcelona |
Contributor_xml | – sequence: 1 fullname: Universitat de Barcelona |
Copyright | The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. (c) Kuck, Karl-Heinz et al., 2016 info:eu-repo/semantics/openAccess The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. 2016 |
Copyright_xml | – notice: The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. – notice: (c) Kuck, Karl-Heinz et al., 2016 info:eu-repo/semantics/openAccess – notice: The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. 2016 |
CorporateAuthor | FIRE AND ICE Investigators |
CorporateAuthor_xml | – name: FIRE AND ICE Investigators |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 XX2 5PM |
DOI | 10.1093/eurheartj/ehw285 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Recercat PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1522-9645 |
EndPage | 2865 |
ExternalDocumentID | PMC5070448 oai_recercat_cat_2072_302080 27381589 10_1093_eurheartj_ehw285 |
Genre | Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAFWJ AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAYXX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGHP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CITATION CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 MHKGH ML0 N9A NGC NOMLY NOYVH NU- NVLIB O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SEL TCURE TEORI TJX W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 ADJQC ADRIX AFXEN CGR CUY CVF ECM EIF M49 NPM 7X8 XX2 5PM |
ID | FETCH-LOGICAL-c504t-4b2923a4899fb0c6769179f3e1e8a376f804d306b2b5f811a80b5584f39ceae33 |
ISSN | 0195-668X 1522-9645 |
IngestDate | Thu Aug 21 18:08:29 EDT 2025 Fri Aug 29 12:43:47 EDT 2025 Fri Jul 11 12:30:19 EDT 2025 Wed Feb 19 02:36:57 EST 2025 Tue Jul 01 03:20:08 EDT 2025 Thu Apr 24 23:08:52 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 38 |
Keywords | Rehospitalization Radiofrequency Cryoballoon Atrial fibrillation Catheter ablation Follow-up |
Language | English |
License | The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c504t-4b2923a4899fb0c6769179f3e1e8a376f804d306b2b5f811a80b5584f39ceae33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://recercat.cat/handle/2072/302080 |
PMID | 27381589 |
PQID | 1826711545 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5070448 csuc_recercat_oai_recercat_cat_2072_302080 proquest_miscellaneous_1826711545 pubmed_primary_27381589 crossref_citationtrail_10_1093_eurheartj_ehw285 crossref_primary_10_1093_eurheartj_ehw285 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-10-07 |
PublicationDateYYYYMMDD | 2016-10-07 |
PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-07 day: 07 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | European heart journal |
PublicationTitleAlternate | Eur Heart J |
PublicationYear | 2016 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Fürnkranz (2016101823583207000_37.38.2858.2) 2014; 25 2016101823583207000_37.38.2858.5 2016101823583207000_37.38.2858.4 2016101823583207000_37.38.2858.7 2016101823583207000_37.38.2858.6 2016101823583207000_37.38.2858.9 2016101823583207000_37.38.2858.8 2016101823583207000_37.38.2858.11 2016101823583207000_37.38.2858.12 2016101823583207000_37.38.2858.13 2016101823583207000_37.38.2858.1 2016101823583207000_37.38.2858.3 2016101823583207000_37.38.2858.10 Wu (2016101823583207000_37.38.2858.14) 2014; 12 27593103 - Eur Heart J. 2016 Oct 7;37(38):2866-2868 |
References_xml | – ident: 2016101823583207000_37.38.2858.8 doi: 10.1161/CIRCULATIONAHA.115.016871 – ident: 2016101823583207000_37.38.2858.6 doi: 10.1016/j.jacc.2011.08.068 – ident: 2016101823583207000_37.38.2858.11 doi: 10.1093/eurheartj/ehn024 – ident: 2016101823583207000_37.38.2858.3 doi: 10.1056/NEJM199809033391003 – ident: 2016101823583207000_37.38.2858.9 doi: 10.1111/j.1540-8159.2004.00620.x – volume: 12 start-page: e2 year: 2014 ident: 2016101823583207000_37.38.2858.14 article-title: Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients publication-title: Health Qual Life Outcomes doi: 10.1186/s12955-014-0156-6 – volume: 25 start-page: 1314 year: 2014 ident: 2016101823583207000_37.38.2858.2 article-title: Rationale and Design of FIRE AND ICE: a multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction publication-title: J Cardiovasc Electrophysiol doi: 10.1111/jce.12529 – ident: 2016101823583207000_37.38.2858.5 doi: 10.1056/NEJMoa1408288 – ident: 2016101823583207000_37.38.2858.4 doi: 10.1093/europace/eus027 – ident: 2016101823583207000_37.38.2858.13 doi: 10.1111/j.1524-4733.2006.00108.x – ident: 2016101823583207000_37.38.2858.10 doi: 10.1161/CIRCULATIONAHA.104.518837 – ident: 2016101823583207000_37.38.2858.12 doi: 10.1186/1471-2261-13-1 – ident: 2016101823583207000_37.38.2858.7 doi: 10.5603/CJ.a2015.0037 – ident: 2016101823583207000_37.38.2858.1 doi: 10.1056/NEJMoa1602014 – reference: 27593103 - Eur Heart J. 2016 Oct 7;37(38):2866-2868 |
SSID | ssj0008616 |
Score | 2.6111436 |
Snippet | The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency... AIMS: The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs.... |
SourceID | pubmedcentral csuc proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2858 |
SubjectTerms | Atrial Fibrillation Cardiac catheterization Cateterisme cardíac Catheter Ablation Cryosurgery Editor's Choice Fast Track Fasttrack Clinical Fibril·lació auricular Humans Pulmonary Veins Quality of Life Radio frequency Radiofreqüència Recurrence Treatment Outcome |
Title | Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27381589 https://www.proquest.com/docview/1826711545 https://recercat.cat/handle/2072/302080 https://pubmed.ncbi.nlm.nih.gov/PMC5070448 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj5NAFJ7UmhhfjHfrLWPii3axUG6Db9rs2nVTHza7Sd_IDB2yVRYaCjHtr_Kn-JM8ZwYo7FajPpS0QGcg52POHOY73yHktS-EF_iWawSxyyFAsZjBAuEZgS_BHdkWxM2YOzz74k3Pnc9zd97r_WyxlspCvIu2e_NK_seqsA_silmy_2DZplHYAd_BvrAFC8P2r2w8yTco55FkOOnLhzlfLLM41-TozZCLZMckXG8uV0Wm9VlXHLkr60uUCdBVO2Ik_idJw_TI5bLFhUQz5PKiqjBSJW7WtE-dlbkxsthIlrEcZmUBt6poXmpSe3R8eqg0rI4nh0PV297FACysXQzbd63Wl_RgfcLzxJjCNW0buOEC_8dJnn4DX7vtZOrsCAulusiT4anKAt89BjNZbKs8H8Xn5J13H5anWHTaP8tqvIZYOvC0ImU9oGsVmQq4WjumHp6Z1om_5je0ppYsc3W3X_H7xfexLibUAtLqUiEJ05ksV5c-uqLWXR-6QW6OIXDBmhqf5jvSEfOserEcuhw1HY50dyhNXTXQmSf1o3UZ7YuBrlJ5W3Ojs7vkThXU0A8aofdIT6b3ya1ZRdt4QH60gEqznHaBSmugUgAqbQGV7oBKNVBpG6jvaRemB_QaSA8oQIJegSitIUqXKQWIUoQoBYhSgChV_Twk50eHZ5OpUZUKMSLXdArDEWOIVLjDgiAWZoS8bfA0sS0tyTj40JiZzgKiYzEWbswsizNTuDD3ju0gklza9iPST7NUPiHUY_bCjETg8yhwmIxEBE5RWgubOdw0F-6AjGrDhFGlo4_lXJJQ8znssLFqqK06IG-af6y0hswfzn2Ltg5huiPziBchyr83P_AzNv1xaGNtXXNAXtWICMEr4FIfT2VWrkN8a-Cj0hY0-FgjpOm6RtiA-B3sNCdgl90j6fJCKc9D8Gg6Dnv62zafkdu75_Q56Rd5KV_ArL0QL9WD8Audevv0 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cryoballoon+or+radiofrequency+ablation+for+symptomatic+paroxysmal+atrial+fibrillation%3A+reintervention%2C+rehospitalization%2C+and+quality-of-life+outcomes+in+the+FIRE+AND+ICE+trial&rft.jtitle=European+heart+journal&rft.au=Kuck%2C+Karl-Heinz&rft.au=F%C3%BCrnkranz%2C+Alexander&rft.au=Chun%2C+K+R+Julian&rft.au=Metzner%2C+Andreas&rft.date=2016-10-07&rft.eissn=1522-9645&rft.volume=37&rft.issue=38&rft.spage=2858&rft_id=info:doi/10.1093%2Feurheartj%2Fehw285&rft_id=info%3Apmid%2F27381589&rft.externalDocID=27381589 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-668X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-668X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-668X&client=summon |